EUCTR2006-003622-29-GB进行中（未招募）1 期
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease - ARRIVE
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 12,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- elevated total cholesterol
- •- low HDL cholesterol
- •- elevated blood pressure
- •- family history of early CHD
- •- on antihypertensive therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- type I and type II diabetes
- •- prior history of a CVD events (clinical or diagnostic)
- •- standard exclusion criterias for ASA (see protocol)
- •- any condition likely to cause death within 5 years
- •- chronic, frequent use of NSAID´s or COX-2 inhibitors
研究者
相似试验
进行中（未招募）
1 期
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind,Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease. - ARRIVEPatients at moderate risk of CHD events (10-20% 10-year riskapproximate 20-30% 10-year risk of CVD).MedDRA version: 9.1Level: LLTClassification code 10028596Term: Myocardial infarctionEUCTR2006-003622-29-ITBAYER12,000
进行中（未招募）
1 期
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease - ARRIVEPatients at moderate risk of CHD events (10-20% 10-year CHD riskapproximately 30% 10-year risk of CVD events based on the underlyingassumption at study start).MedDRA version: 19.0Level: LLTClassification code 10072760Term: Transient ischemic attackSystem Organ Class: 100000004852MedDRA version: 19.0Level: LLTClassification code 10042244Term: StrokeSystem Organ Class: 100000004852MedDRA version: 19.0Level: LLTClassification code 10046251Term: Unstable anginaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.0Level: PTClassification code 10028596Term: Myocardial infarctionSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.0Level: PTClassification code 10049993Term: Cardiac deathSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2006-003622-29-DEBayer AG12,000
进行中（未招募）
1 期
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, arallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease - ARRIVEEUCTR2006-003622-29-IEBayer Consumer Care AG12,000
进行中（未招募）
1 期
Estudio ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, aspirina para reducir el riesgo de accidentes vasculares iniciales) – Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico y de grupos paralelos para evaluar la eficacia (reducción de los acontecimientos de enfermedad cardiovascular) y la seguridad de 100 mg ácido de acetilsalicílico con recubrimiento entérico en pacientes con riesgo moderado de sufrir enfermedad cardiovascular. - ARRIVEEUCTR2006-003622-29-ESBayer HealhCare AG12,000
进行中（未招募）
1 期
Investigating the Role of Early Low-dose Aspirin in DiabetesEUCTR2018-000770-29-IEThe Rotunda Hospital360